Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2026Annals of HematologyOpen Access

In-hospital mortality and complications are increased in hematopoietic stem cell transplant recipients with myelodysplastic syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAniket Vijay RaoASAditya SanjeeviDIDaniel Jose Idoate-Domench

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds higher mortality and complications in MDS patients undergoing HSCT, suggesting care gaps.

Key Points

  • This study aims to analyze trends, outcomes, and barriers to hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
  • Retrospective analysis of the National Inpatient Sample from 2016 to 2020
  • Identification of adult patients undergoing allogeneic HSCT using ICD-10 codes
  • Comparison of characteristics and outcomes using Pearson Chi-square and t-tests, adjusted with propensity score matching.
  • Among 30,460 patients, 4,980 (16.16%) had MDS, with higher comorbidity burdens and in-hospital mortality (aOR 1.33, 95% CI 1.14-1.55).
  • MDS patients experienced greater complications like mechanical ventilation (aOR 1.30) and acute GVHD (aOR 1.26).
  • Insurance disparities were noted, with 38.73% of MDS patients insured through Medicare compared to 17.10% in non-MDS patients.

Cite This Study

Rao et al. (2026) studied this question.

synapsesocial.com/papers/6a2e46dbb1cc60ccdea8b798https://doi.org/10.1007/s00277-026-07058-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1National Trends and In-Hospital Outcomes of Hematopoietic Stem Cell Transplant in Myelodysplastic Syndromes, 2016–20202025
  2. 2Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025
  3. 3Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes2025
  4. 4Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review2025
  5. 5Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience2025